Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc.（TSHA）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · TSHA · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
14
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Taysha Gene Therapies, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
TSHA 季度内部人买卖趋势
TSHA 内幕交易卖出 · TSHA 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · TSHA CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
TSHA 高管卖出股份 · TSHA 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Stalfort John A III Director | Award | 21,335 | — | Form 4 |
| Jun 1, 2026 | Donenberg Phillip B. Director | Award | 21,335 | — | Form 4 |
| Jun 1, 2026 | Long Alison S Director | Award | 21,335 | — | Form 4 |
| Jun 1, 2026 | Sepp-Lorenzino Laura Director | Award | 21,335 | — | Form 4 |
| Apr 10, 2026 | Nagendran Sukumar President and Head of R&D · Director | Option | 19,021 | $33K | Form 4 |
| Apr 10, 2026 | Nagendran Sukumar President and Head of R&D · Director | Sale | 200,000 | $892K | Form 4 |
| Feb 4, 2026 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | 1,655 | $7K | Form 4 |
| Jan 23, 2026 | Nagendran Sukumar President and Head of R&D · Director | Sale | 89,132 | $423K | Form 4 |
| Jan 26, 2026 | Nagendran Sukumar President and Head of R&D · Director | Sale | 26,918 | $124K | Form 4 |
| Jan 23, 2026 | Nolan Sean P. CEO · Director | Sale | 136,789 | $650K | Form 4 |
| Jan 26, 2026 | Nolan Sean P. CEO · Director | Sale | 41,312 | $190K | Form 4 |
| Jan 23, 2026 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | 78,968 | $375K | Form 4 |
| Jan 26, 2026 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | 23,849 | $110K | Form 4 |
| Jan 12, 2026 | Alam Kamran CHIEF FINANCIAL OFFICER | Award | 359,000 | — | Form 4 |
| Jan 12, 2026 | Nolan Sean P. CEO · Director | Award | 1,008,000 | — | Form 4 |
| Jan 12, 2026 | Nagendran Sukumar President and Head of R&D · Director | Award | 427,000 | — | Form 4 |
| Jan 12, 2026 | Nagendran Sukumar President and Head of R&D · Director | Option | 88,676 | $152K | Form 4 |
| Jan 12, 2026 | Nagendran Sukumar President and Head of R&D · Director | Option | 111,324 | $78K | Form 4 |
| Jan 12, 2026 | Nagendran Sukumar President and Head of R&D · Director | Sale | 200,000 | $942K | Form 4 |
| Dec 1, 2025 | Nagendran Sukumar President and Head of R&D · Director | Option | 260,047 | $445K | Form 4 |
| Nov 28, 2025 | Nagendran Sukumar President and Head of R&D · Director | Option | 39,953 | $68K | Form 4 |
| Nov 28, 2025 | Nagendran Sukumar President and Head of R&D · Director | Option | 70,172 | $49K | Form 4 |
| Nov 28, 2025 | Nagendran Sukumar President and Head of R&D · Director | Sale | 110,125 | $523K | Form 4 |
| Dec 1, 2025 | Nagendran Sukumar President and Head of R&D · Director | Sale | 260,047 | $1.17M⚡ | Form 4 |
| Sep 10, 2025 | Nagendran Sukumar President and Head of R&D · Director | Option | 41,150 | $29K | Form 4 |
Nagendran Sukumar
President and Head of R&D · Director
日期
Apr 10
股数
19,021
均价
$1.71
总金额
$33K
Nagendran Sukumar
President and Head of R&D · Director
日期
Apr 10
股数
200,000
均价
$4.46
总金额
$892K
Nagendran Sukumar
President and Head of R&D · Director
日期
Jan 23
股数
89,132
均价
$4.75
总金额
$423K
Nagendran Sukumar
President and Head of R&D · Director
日期
Jan 26
股数
26,918
均价
$4.61
总金额
$124K
Nagendran Sukumar
President and Head of R&D · Director
日期
Jan 12
股数
427,000
均价
—
总金额
—
Nagendran Sukumar
President and Head of R&D · Director
日期
Jan 12
股数
88,676
均价
$1.71
总金额
$152K
Nagendran Sukumar
President and Head of R&D · Director
日期
Jan 12
股数
111,324
均价
$0.70
总金额
$78K
Nagendran Sukumar
President and Head of R&D · Director
日期
Jan 12
股数
200,000
均价
$4.71
总金额
$942K
Nagendran Sukumar
President and Head of R&D · Director
日期
Dec 1
股数
260,047
均价
$1.71
总金额
$445K
Nagendran Sukumar
President and Head of R&D · Director
日期
Nov 28
股数
39,953
均价
$1.71
总金额
$68K
Nagendran Sukumar
President and Head of R&D · Director
日期
Nov 28
股数
70,172
均价
$0.70
总金额
$49K
Nagendran Sukumar
President and Head of R&D · Director
日期
Nov 28
股数
110,125
均价
$4.75
总金额
$523K
Nagendran Sukumar
President and Head of R&D · Director
日期
Dec 1
股数
260,047
均价
$4.51
总金额
$1.17M ⚡
Nagendran Sukumar
President and Head of R&D · Director
日期
Sep 10
股数
41,150
均价
$0.70
总金额
$29K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 TSHA 内幕交易
TSHA 内幕交易
Taysha Gene Therapies, Inc.（TSHA）内幕交易数据来源于公司内部人（包括Nagendran Sukumar (President and Head of R&D · Director), Alam Kamran (CHIEF FINANCIAL OFFICER), Nolan Sean P. (CEO · Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。TSHA内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Taysha Gene Therapies, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
TSHA 内幕交易 · 5个问题Taysha Gene Therapies, Inc.（TSHA）的内部人包括高管和董事，如Nagendran Sukumar (President and Head of R&D · Director), Alam Kamran (CHIEF FINANCIAL OFFICER), Nolan Sean P. (CEO · Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026